SCHEMBL118559

SCHEMBL118559

O=C(Cc1ccc2[nH]nnc2c1)N1CCC(N2CCN(C(=O)Nc3cc(Cl)cc(Cl)c3)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.42
PKM P14618 2/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
CCR3 P51677 1/20 0.40
CCR2 P41597 3/20 0.39
KCNH2 Q12809 2/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 3/20 0.39
HRH3 Q9Y5N1 1/20 0.38
GOT1 P17174 1/20 0.38
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
EPHX2 P34913 1/20 0.37
FAAH O00519 1/20 0.37
NPC1 O15118 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14889464 0.88 CCR3 (0.38) PKMCCR3ALDH1A1KDM4EACACB
SCHEMBL15996442 0.86 NAMPT (0.43) NPSR1PKMCYP3A4CYP2D6CYP2C19
SCHEMBL118063 0.86 NAMPT (0.43) NPSR1PKMCYP3A4CYP2D6CYP2C19
SCHEMBL14889443 0.83 ALDH1A1 (0.48) PKMCYP2C19MAPTCCR3ALDH1A1
SCHEMBL118987 0.79 CNR1 (0.45) NPSR1PKMCYP3A4CYP2D6CYP2C19
SCHEMBL117573 0.78 TACR1 (0.43) PKMALDH1A1KDM4EHRH3ACACB
SCHEMBL358101 0.76 POLB (0.50) POLBALDH1A1KDM4EFAAHSMN1; SMN2
SCHEMBL118338 0.75 ENPP2 (0.52) CCR3HRH3
SCHEMBL118732 0.75 ENPP2 (0.41) KCNH2
SCHEMBL14889446 0.74 ENPP2 (0.41) CCR3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452997-B2 Piperidine and piperazine derivatives as autotaxin inhibitors MERCK PATENT GMBH (DE) 2016-09-27 US disclosed
US-9452997-B2 Piperidine and piperazine derivatives as autotaxin inhibitors MERCK PATENT GMBH (DE) 2016-09-27 US disclosed
US-20140343075-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS MERCK PATENT GMBH (DE) 2014-11-20 US disclosed
US-20140343075-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS MERCK PATENT GMBH (DE) 2014-11-20 US disclosed
US-8822476-B2 Piperidine and piperazine derivatives as autotaxin inhibitors MERCK PATENT GMBH (DE) 2014-09-02 US disclosed
US-8822476-B2 Piperidine and piperazine derivatives as autotaxin inhibitors MERCK PATENT GMBH (DE) 2014-09-02 US disclosed
US-20120059016-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-08 US disclosed
US-20120059016-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-08 US disclosed
US-20120059016-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343075-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS ENPP2, PLA2G12A, PLA2G2E NPSR1 1942/4885PKM 3473/4885CYP3A4 4792/4885
US-20120059016-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS ENPP2, PLA2G12A, PLA2G2E NPSR1 1942/4885PKM 3473/4885CYP3A4 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.